ADMA Biologics grants CFO RSUs and options

ADMA Biologics CFO and Treasurer Terry Kohler received equity awards on July 16, 2026.

Rhea-AI Filing Summary

ADMA Biologics CFO and Treasurer Terry Kohler received equity awards on July 16, 2026. He was granted 85,130 restricted stock units (RSUs) that vest over four years, bringing his unvested RSUs to 143,149, including 58,019 from a December 8, 2025 grant. He also received a stock option for 136,363 shares of common stock at an exercise price of $8.81 per share, vesting 25% after one year and the remainder in substantially equal monthly installments through July 16, 2030, with an expiration date of July 16, 2036.

Insider Trade Summary

Grant/Award: 221,493 shares

Grant/Award 2 txns

Insider Kohler Terry

Role CFO and Treasurer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F3	136,363	$0.00	$0.00
Grant/Award	Common Stock F1, F2	85,130	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 136,363 contracts (Direct); Common Stock — 143,149 shares (Direct)

Footnotes (3)

1. F1. These shares represent restricted stock units ("RSUs") that will vest quarterly on each annual anniversary of the date of grant over four years in accordance with the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the "Plan"), subject to the Reporting Person's continued service as of the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
2. F2. Includes, as of the transaction date, (i) 85,130 unvested RSUs granted on July 16, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (ii) 58,019 unvested RSUs granted on December 8, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
3. F3. This option was granted to the Reporting Person on July 16, 2026, and will vest over four years, with 25% of the shares subject to the option vesting on the one-year anniversary of the date of grant, and the remaining 75% of the shares subject to the option vesting over the subsequent three-year period in substantially equal monthly installments at a rate of 1/48th of the total shares subject to the option each month, becoming fully vested on July 16, 2030 in accordance with the Plan, subject to the Reporting Person's continued service as of the applicable vesting date.

Key Figures

RSUs granted July 16, 2026: 85,130 units Unvested RSUs after grant: 143,149 units Prior unvested RSUs from Dec. 8, 2025: 58,019 units +4 more

7 metrics

RSUs granted July 16, 2026 85,130 units Restricted stock units granted to CFO Terry Kohler on July 16, 2026

Unvested RSUs after grant 143,149 units Total unvested RSUs held by Terry Kohler as of July 16, 2026

Prior unvested RSUs from Dec. 8, 2025 58,019 units Unvested RSUs from December 8, 2025 grant included in total holdings

Stock options granted 136,363 shares Shares underlying stock option granted July 16, 2026 to Terry Kohler

Option exercise price $8.81 per share Exercise price of stock option granted July 16, 2026

Option expiration date July 16, 2036 Expiration date of stock option granted to Terry Kohler

Full option vesting date July 16, 2030 Date on which stock option becomes fully vested, subject to continued service

Key Terms

restricted stock units, Stock Option (Right to Buy), 2022 Equity Compensation Plan, contingent right to receive one share

4 terms

restricted stock units financial

"These shares represent restricted stock units ("RSUs") that will vest over four years"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Stock Option (Right to Buy) financial

"Transaction in a Stock Option (Right to Buy) with underlying common stock"

2022 Equity Compensation Plan financial

"in accordance with the ADMA Biologics, Inc. 2022 Equity Compensation Plan"

contingent right to receive one share financial

"Each RSU represents a contingent right to receive one share of common stock"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did ADMA (ADMA) CFO Terry Kohler receive on July 16, 2026?

Terry Kohler received 85,130 restricted stock units and a stock option for 136,363 shares on July 16, 2026. The RSUs and options are subject to multi‑year vesting schedules tied to his continued service with ADMA Biologics.

How do Terry Kohler’s new RSUs at ADMA (ADMA) vest over time?

The 85,130 RSUs granted to Terry Kohler vest over four years, subject to his continued service on each applicable vesting date. Each RSU represents a contingent right to receive one share of ADMA Biologics common stock upon vesting.

What is the size and exercise price of the new stock option granted to ADMA (ADMA) CFO Terry Kohler?

Kohler received a stock option covering 136,363 shares of ADMA common stock with an exercise price of $8.81 per share. The option was granted on July 16, 2026 and provides the right to buy shares at that price upon vesting.

What is Terry Kohler’s total unvested RSU position in ADMA (ADMA) after this grant?

After the July 16, 2026 grant, Kohler holds 143,149 unvested RSUs. This includes 85,130 RSUs granted on July 16, 2026 and 58,019 RSUs from a December 8, 2025 grant, all subject to continued service-based vesting.

When do Terry Kohler’s new ADMA (ADMA) stock options fully vest and expire?

The stock option becomes fully vested on July 16, 2030, assuming Kohler’s continued service. Vesting occurs 25% after one year, then in substantially equal monthly installments. The option expires July 16, 2036 if not exercised earlier.

Under which plan were the new ADMA (ADMA) awards to Terry Kohler granted?

Both the RSUs and stock option were granted under the ADMA Biologics, Inc. 2022 Equity Compensation Plan. The plan governs vesting conditions and settlement of RSUs into common stock and the terms of stock options awarded to Kohler.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/17/2026 - 09:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kohler Terry

(Last) (First) (Middle)

C/O ADMA BIOLOGICS, INC.

5800 PARK OF COMMERCE BLVD. NW

(Street)

BOCA RATON FLORIDA 33487

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ADMA BIOLOGICS, INC. [ ADMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO and Treasurer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/16/2026		A		85,130(1)	A	$0	143,149(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8.81	07/16/2026		A		136,363		(3)	07/16/2036	Common Stock	136,363	$0	136,363	D

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs") that will vest quarterly on each annual anniversary of the date of grant over four years in accordance with the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the "Plan"), subject to the Reporting Person's continued service as of the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

2. Includes, as of the transaction date, (i) 85,130 unvested RSUs granted on July 16, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (ii) 58,019 unvested RSUs granted on December 8, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

3. This option was granted to the Reporting Person on July 16, 2026, and will vest over four years, with 25% of the shares subject to the option vesting on the one-year anniversary of the date of grant, and the remaining 75% of the shares subject to the option vesting over the subsequent three-year period in substantially equal monthly installments at a rate of 1/48th of the total shares subject to the option each month, becoming fully vested on July 16, 2030 in accordance with the Plan, subject to the Reporting Person's continued service as of the applicable vesting date.

	/s/ Terry Kohler, by Michael A. Goldstein as Attorney-in-fact	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)